Tirzepatide

Zepbound is FDA approved for long-term weight management in eligible adults and for moderate-to-severe obstructive sleep apnea in adults with obesity. Approval is for the labeled tirzepatide product and populations.^[1]

Jurisdiction

United States

Product

ZEPBOUND (tirzepatide)

Indication

Adult chronic weight management meeting label criteria and moderate-to-severe obstructive sleep apnea in adults with obesity

Record date

2026-09-08

• This does not establish efficacy or quality of unapproved tirzepatide products.

Zepbound carries a boxed warning for thyroid C-cell tumors and is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2. The warning derives from rat findings; human relevance remains uncertain. The current label records removal of the suicidal-behavior/ideation warning in February 2026.^[1]

• A rodent tumor finding should not be presented as established human thyroid-cancer causation; this summary is not the complete label.

Zepbound labeling warns of hypoglycemia, with increased risk when tirzepatide is combined with insulin or insulin secretagogues.^[1]

• This is a product-label warning, not a study of every possible drug pair.

Zepbound can cause severe gastrointestinal reactions and is not recommended with severe gastroparesis. Its label describes postmarketing acute kidney injury reports, mostly following gastrointestinal symptoms that led to dehydration.^[1]

• Postmarketing reports do not provide a reliable incidence or prove causality in every case.

Zepbound labeling warns that pulmonary aspiration has been reported rarely in patients receiving GLP-1 receptor agonists during general anesthesia or deep sedation, in some cases despite reported adherence to preoperative fasting. The label states available data are insufficient to recommend specific fasting or drug-discontinuation changes to reduce this risk.^[1]

• These are rare postmarketing reports, not an established incidence rate or a tested mitigation protocol.

FDA has reported that, as of May 31, 2026, it had received more than 730 adverse-event reports associated with compounded tirzepatide products. FDA states it cannot always determine whether the drug directly caused a reported event, and that compounded products are not FDA-approved or reviewed for safety, effectiveness or quality before marketing.^[3]

• A raw report count is not an incidence rate, is likely affected by underreporting (state-licensed non-outsourcing pharmacies need not report to FDA), and describes compounded products rather than the FDA-approved Zepbound/Mounjaro products.

Zepbound’s label reports a tirzepatide elimination half-life of approximately 5–6 days in people with overweight or obesity, including those with obstructive sleep apnea.^[1]

• This is the labeled subcutaneous formulation; it does not establish oral-product pharmacokinetics.

In SURMOUNT-1, mean weight change at 72 weeks ranged from −15.0% to −20.9% across tirzepatide dose groups versus −3.1% with placebo in adults without diabetes. Gastrointestinal adverse events were common.^[2]

• The figures are trial-specific averages, not a personalized outcome or evidence of superiority to another medicine.
• Only the published abstract was inspected; no PMC full text exists for this article, so full methods, tables and supplementary appendices were not reviewed.

A Bayesian network meta-analysis published in 2025 pooled 19 randomized controlled trials covering 29,506 adults with a body-mass index of 25 kg/m2 or more, comparing liraglutide, semaglutide, survodutide, tirzepatide, retatrutide and placebo at 36 weeks or later. Its abstract reports that retatrutide and the dual agonists produced equivalent mean weight loss of 11.0 kg, more than the GLP-1 receptor agonists at 9.0 kg, and that for reaching at least 15% weight loss the odds ratios were 54.6 for retatrutide, 16.4 for the dual agonists and 9.0 for the GLP-1 receptor agonists. It also reports that retatrutide carried the highest risk of adverse events, and that in meta-regression the presence of type 2 diabetes was associated with less weight loss. These are indirect comparisons across trials, not head-to-head results.^[4]

• Abstract-only inspection. The included-trial list, risk-of-bias assessment, network structure and heterogeneity statistics were not read, because no lawful full-text copy was reachable.
• The abstract does not name the 19 pooled trials or state their development phase, so this record cannot show which trial of any compound contributed to which estimate. The survodutide and retatrutide results recorded elsewhere in this reference come from phase 2 dose-finding trials, the same records also list completed phase 3 trials of both compounds, and semaglutide and tirzepatide are approved for weight management, so the pooled classes may combine evidence of unequal maturity.
• A network meta-analysis estimates comparisons between treatments that were mostly never tested against each other. Its rankings are model outputs, not measured differences.
• The GLP-1 receptor agonists and the dual agonists are pooled by class in the reported results, so the abstract gives no separate estimate for semaglutide, survodutide or tirzepatide; retatrutide is reported on its own because the abstract treats it as a group of one.
• The meta-regression associations are observational comparisons across trials, not randomized ones.
• This finding is recorded as cross-compound context. It is not evidence about any single compound's own trial results, which are recorded separately on each record.

ZEPBOUND labeling warns of increased hypoglycemia risk when tirzepatide is used with insulin and calls for consideration of a clinician-directed insulin reduction.^[1]

• A label warning for insulin coadministration, not a separate trial of every insulin preparation.

ZEPBOUND labeling does not recommend coadministration with another tirzepatide product or a GLP-1 receptor agonist such as semaglutide.^[1]

• Not classified as a formal contraindication; no amount of additive toxicity is established.